^
    Apply
    Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer (NCT04989946)
    Phase 1/2
    University of Wisconsin, Madison
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    12/16/2021
    Primary completion :
    12/01/2026
    Completion :
    12/01/2028
    CD8
    |
    Opdivo (nivolumab) • Libtayo (cemiplimab-rwlc) • Firmagon (degarelix) • fianlimab (REGN3767) • MVI-118
    A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer (NCT05800015)
    Phase 2/3
    Regeneron Pharmaceuticals
    Recruiting
    Last update posted :
    01/31/2025
    Initiation :
    08/08/2023
    Primary completion :
    01/16/2030
    Completion :
    12/23/2031
    PD-L1
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT06769698)
    Phase 2
    Regeneron Pharmaceuticals
    Not yet recruiting
    Last update posted :
    01/10/2025
    Initiation :
    03/26/2025
    Primary completion :
    04/22/2027
    Completion :
    11/28/2029
    PD-L1
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2) (NCT01042379)
    Phase 2
    QuantumLeap Healthcare Collaborative
    Recruiting
    Last update posted :
    10/22/2024
    Initiation :
    03/01/2010
    Primary completion :
    12/01/2030
    Completion :
    12/01/2031
    HER-2 • ER
    |
    ER positive • ER negative
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1
    A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) (R3767-ONC-2235) (NCT05785767)
    Phase 2/3
    Regeneron Pharmaceuticals
    Recruiting
    Last update posted :
    05/29/2024
    Initiation :
    06/30/2023
    Primary completion :
    03/11/2030
    Completion :
    02/05/2032
    PD-L1
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL) (NCT04566978)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    10/17/2023
    Initiation :
    09/11/2020
    Primary completion :
    09/11/2025
    Completion :
    09/11/2025
    LAG3
    |
    LAG3 expression
    |
    fianlimab (REGN3767)